We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




FOXO Protein Deficiency Linked to Osteoarthritis Severity

By LabMedica International staff writers
Posted on 03 Mar 2018
A mouse model that had been genetically engineered to lack FOXO (Forkhead box) proteins in cartilage was found to exhibit worse arthritis with aging and increased cartilage degradation in response to surgically induced arthritis.

Aging is a main risk factor for osteoarthritis (OA). More...
FoxO transcription factors are known to protect against cellular and organismal aging, and FoxO expression in cartilage is reduced with aging and in OA. To investigate the role of FoxO in cartilage, investigators at The Scripps Research Institute (La Jolla, CA, USA) genetically engineered mice with FoxO deficiency in their cartilage tissue.

The investigators reported in the February 14, 2018, online edition of the journal Science Translational Medicine that these mice exhibited worse arthritis with aging and increased cartilage degradation in response to surgically induced arthritis. In addition, they expressed less lubricin, a protein that helps reduce friction in joints. The FoxO-deficient mice also had defects in autophagy and in mechanisms that normally protect cells from damage by oxidants.

FoxO1 and autophagy-related genes were found to be reduced in human chondrocytes from patients with osteoarthritis, and restoring FoxO1 expression reduced inflammatory cytokines and increased lubricin production.

"We discovered that FoxO transcription factors control the expression of genes that are essential for maintaining joint health," said senior author Dr. Martin Lotz, a professor at The Scripps Research Institute. "The housekeeping mechanisms, which keep cells healthy, were not working in these knockout mice. Drugs that boost the expression and activity of FoxO could be a strategy for preventing and treating osteoarthritis."

Related Links:
The Scripps Research Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
All-in-One Molecular System
AIO M160
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.